| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 68.73% | 5.43% | 41.69% | 34.15% | 40.64% |
| Operating Margin | -293.46% | -252.32% | -271.14% | — | — | — | — | -345.90% | -769.17% | -423.24% | -315.96% | -654.90% |
| EBITDA Margin | -284.92% | -239.90% | -258.36% | — | — | — | — | -291.31% | -689.18% | -397.85% | -293.37% | -639.17% |
| Net Margin | -429.43% | -222.84% | -271.04% | — | — | — | — | -344.16% | -843.66% | -473.50% | -387.43% | -754.45% |
| Current Ratio | 1.23 | 0.34 | 0.92 | 1.84 | 3.36 | 1.07 | 1.37 | 0.55 | 0.81 | 1.50 | 2.52 | 1.36 |
| Quick Ratio | 1.23 | 0.34 | 0.92 | 1.84 | 3.36 | 1.07 | 1.36 | 0.38 | 0.63 | 1.20 | 2.01 | 1.06 |
| Debt / Equity | — | — | -2.95 | 0.84 | 0.61 | 2.09 | 9.53 | 2.72 | 1.05 | 0.60 | 0.00 | -1.29 |
| ROE | -560.21% | 145.02% | 987.83% | -314.58% | -123.65% | -271.89% | -938.53% | -241.80% | -174.51% | -200.67% | -153.56% | 655.35% |
| ROA | -137.13% | -195.66% | -116.93% | -84.95% | -60.96% | -68.08% | -46.87% | -52.66% | -71.76% | -63.70% | -49.72% | -96.51% |
| Asset Turnover | 0.32 | 0.88 | 0.43 | — | — | — | — | 0.15 | 0.09 | 0.13 | 0.13 | 0.13 |
| Book Value / Share | 1.28 | -29.05 | -10.73 | 92.05 | 336.13 | — | — | 11270.43 | 75255.10 | 119130.36 | 243821.23 | -198400.80 |
Plus Therapeutics Inc is a clinical-stage pharmaceutical company specializing in the discovery, development, commercialization, and delivery of complex treatments for patients with cancer and rare diseases. The company concentrates on innovative, targeted radiotherapeutics for adults and children facing difficult-to-treat cancers, utilizing novel drug formulations and technologies to deliver a single, safe, and effective dose of radiation directly to the tumor. Its primary programs address recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers, with a key candidate being rhenium (186Re) obisbemeda designed specifically for central nervous system cancers. Operating within the biotechnology sector of healthcare, Plus Therapeutics Inc advances therapies aimed at improving outcomes in oncology and rare disease areas. Headquartered in Houston, Texas, the company focuses on precision medicine approaches to enhance treatment efficacy for challenging medical conditions.